Prognostic Value of the PARIS Thrombotic Risk Score for 2-Year Mortality After Percutaneous Coronary Intervention

Area of Science:

• Cardiology
• Interventional Cardiology
• Clinical Risk Stratification

Background:

• Percutaneous coronary intervention (PCI) is a common procedure for coronary artery disease.
• Predicting thrombotic risk after PCI is crucial for patient management.
• The Patterns of non-Adherence to Anti-Platelet Regimen in Stented Patients (PARIS) score is a novel tool for assessing this risk.

Purpose of the Study:

• To evaluate the prognostic value of the PARIS thrombotic risk score for mortality and major adverse cardiovascular and cerebrovascular events (MACCE) in patients undergoing PCI.
• To compare the prognostic performance of the PARIS score for mortality versus MACCE.

Main Methods:

• A prospective, observational study enrolled 10,724 consecutive patients undergoing PCI.
• The primary endpoint was all-cause death; the secondary endpoint was MACCE (death, myocardial infarction, revascularization, stent thrombosis, or stroke).
• Statistical analysis included hazard ratios and area under the receiver operating characteristic curve (AUROC) to assess prognostic value.

Main Results:

• In 9782 patients without in-hospital events, the high-risk PARIS score group had 2.31 times higher mortality risk (P = .001).
• The PARIS score demonstrated prognostic value for mortality (AUROC, 0.607) and MACCE (AUROC, 0.544) (P < .001 for both).
• The score's prognostic value for mortality was significantly better than for MACCE (P = .04).

Conclusions:

• The PARIS thrombotic risk score has modest prognostic value for predicting mortality and MACCE in patients after PCI.
• The score appears more effective in predicting all-cause mortality compared to the composite MACCE endpoint.
• This suggests the PARIS score can aid in identifying high-risk individuals for closer monitoring post-PCI.